137 related articles for article (PubMed ID: 22188815)
21. How IGF-II Binds to the Human Type 1 Insulin-like Growth Factor Receptor.
Xu Y; Kirk NS; Venugopal H; Margetts MB; Croll TI; Sandow JJ; Webb AI; Delaine CA; Forbes BE; Lawrence MC
Structure; 2020 Jul; 28(7):786-798.e6. PubMed ID: 32459985
[TBL] [Abstract][Full Text] [Related]
22. Marine Bromophenol Bis(2,3,6-Tribromo-4,5-Dihydroxybenzyl)ether Inhibits Angiogenesis in Human Umbilical Vein Endothelial Cells and Reduces Vasculogenic Mimicry in Human Lung Cancer A549 Cells.
Dong S; Chen Z; Wang L; Liu Y; Stagos D; Lin X; Liu M
Mar Drugs; 2021 Nov; 19(11):. PubMed ID: 34822512
[TBL] [Abstract][Full Text] [Related]
23. The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy.
Ma H; Zhang T; Shen H; Cao H; Du J
Br J Clin Pharmacol; 2014 Jun; 77(6):917-28. PubMed ID: 24033707
[TBL] [Abstract][Full Text] [Related]
24. An anti vimentin antibody promotes tube formation.
Jørgensen ML; Møller CK; Rasmussen L; Boisen L; Pedersen H; Kristensen P
Sci Rep; 2017 Jun; 7(1):3576. PubMed ID: 28620205
[TBL] [Abstract][Full Text] [Related]
25. Phosphoproteomic profiling identifies DNMT1 as a key substrate of beta IV spectrin-dependent ERK/MAPK signaling in suppressing angiogenesis.
Flores PC; Ahmed T; Podgorski J; Ortiz HR; Langlais PR; Mythreye K; Lee NY
Biochem Biophys Res Commun; 2024 Jun; 711():149916. PubMed ID: 38613866
[TBL] [Abstract][Full Text] [Related]
26. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.
Ozawa CR; Banfi A; Glazer NL; Thurston G; Springer ML; Kraft PE; McDonald DM; Blau HM
J Clin Invest; 2004 Feb; 113(4):516-27. PubMed ID: 14966561
[TBL] [Abstract][Full Text] [Related]
27. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.
Rudge JS; Holash J; Hylton D; Russell M; Jiang S; Leidich R; Papadopoulos N; Pyles EA; Torri A; Wiegand SJ; Thurston G; Stahl N; Yancopoulos GD
Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18363-70. PubMed ID: 18000042
[TBL] [Abstract][Full Text] [Related]
28. Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy.
Bid HK; London CA; Gao J; Zhong H; Hollingsworth RE; Fernandez S; Mo X; Houghton PJ
Clin Cancer Res; 2013 Jun; 19(11):2984-94. PubMed ID: 23549869
[TBL] [Abstract][Full Text] [Related]
29. IGF-1R targeting in cancer - does sub-cellular localization matter?
Soni UK; Jenny L; Hegde RS
J Exp Clin Cancer Res; 2023 Oct; 42(1):273. PubMed ID: 37858153
[TBL] [Abstract][Full Text] [Related]
30. Relationship between insulin-like growth factor-1 and cerebral small vessel disease and its mechanisms: advances in the field.
Du H; Xia J; Huang L; Zheng L; Gu W; Yi F
Front Aging Neurosci; 2023; 15():1190869. PubMed ID: 37358957
[TBL] [Abstract][Full Text] [Related]
31. Effect of insulin-like growth factor system on luteinising angiogenesis.
Nwachukwu CU; Robinson RS; Woad KJ
Reprod Fertil; 2023 Mar; 4(2):. PubMed ID: 37052337
[TBL] [Abstract][Full Text] [Related]
32. Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma.
Shackleford TJ; Hariharan S; Vaseva AV; Alagoa K; Espinoza M; Bid HK; Li F; Zhong H; Phelps DA; Roberts RD; Cam H; London CA; Guttridge DC; Chen Y; Rao M; Shiio Y; Houghton PJ
Mol Cancer Ther; 2023 Apr; 22(4):539-550. PubMed ID: 36696581
[TBL] [Abstract][Full Text] [Related]
33.
Hong JY; Kim H; Yeo C; Jeon WJ; Lee J; Baek SH; Lee YJ; Ha IH
Antioxidants (Basel); 2022 Jul; 11(7):. PubMed ID: 35883879
[No Abstract] [Full Text] [Related]
34. Angiogenesis in adipose tissue and obesity.
Corvera S; Solivan-Rivera J; Yang Loureiro Z
Angiogenesis; 2022 Nov; 25(4):439-453. PubMed ID: 35857195
[TBL] [Abstract][Full Text] [Related]
35. Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma.
Khurshid S; Montes M; Comiskey DF; Shane B; Matsa E; Jung F; Brown C; Bid HK; Wang R; Houghton PJ; Roberts R; Rigo F; Chandler D
NPJ Precis Oncol; 2022 Jan; 6(1):1. PubMed ID: 35017650
[TBL] [Abstract][Full Text] [Related]
36. A robust vasculogenic microfluidic model using human immortalized endothelial cells and Thy1 positive fibroblasts.
Wan Z; Zhang S; Zhong AX; Shelton SE; Campisi M; Sundararaman SK; Offeddu GS; Ko E; Ibrahim L; Coughlin MF; Liu T; Bai J; Barbie DA; Kamm RD
Biomaterials; 2021 Sep; 276():121032. PubMed ID: 34303155
[TBL] [Abstract][Full Text] [Related]
37. Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets.
De A; De A; Sharma R; Suo W; Sharma M
J Cancer; 2020; 11(7):1927-1939. PubMed ID: 32194804
[No Abstract] [Full Text] [Related]
38. Establishment of a novel human CIC-DUX
Nakai S; Yamada S; Outani H; Nakai T; Yasuda N; Mae H; Imura Y; Wakamatsu T; Tamiya H; Tanaka T; Hamada K; Tani A; Myoui A; Araki N; Ueda T; Yoshikawa H; Takenaka S; Naka N
Sci Rep; 2019 Nov; 9(1):15812. PubMed ID: 31676869
[TBL] [Abstract][Full Text] [Related]
39. Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey.
Crudden C; Song D; Cismas S; Trocmé E; Pasca S; Calin GA; Girnita A; Girnita L
Cells; 2019 Oct; 8(10):. PubMed ID: 31600876
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Targeting of the IGF Axis.
Osher E; Macaulay VM
Cells; 2019 Aug; 8(8):. PubMed ID: 31416218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
